Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2011. The report details a specific share repurchase transaction executed on May 19, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 350,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,337.50 pence per share; lowest price paid was 1,324.00 pence per share.
- Treasury Holdings (Settled): 493,574,284 shares (8.73% of total issued share capital).
- Treasury Holdings (Including Unsettled): 494,799,284 shares (9.58% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,162,820,394 shares.
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 350,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 9.58% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,162,820,394) for calculating disclosure thresholds under FSA rules.
- Confirm the current percentage of voting rights held in Treasury (9.58% including unsettled shares).
- Review the price paid per share (1,324.00 to 1,337.50 pence) against market prices on May 19, 2011.
- Note that this filing does not contain financial performance data; refer to Form 20-F for full financial statements.